|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Net product revenue | |||||
| Collaboration revenue | |||||
| Milestone revenue | |||||
| Total Revenue | |||||
| Operating expenses: | |||||
| Cost of product sales | |||||
| Research and development expenses | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Royalty interest expense | |||||
| Other interest (expense) income | |||||
| Interest income | |||||
| Other expense, net | |||||
| Total other income | |||||
| Net income | |||||
| Net loss attributable to common stockholders | |||||
| Net loss Per Share: | |||||
| Basic loss per share attributable to common stockholders | |||||
| Diluted loss per share attributable to common stockholders | |||||
| Weighted-average common shares used in calculating: | |||||
| Basic loss per share attributable to common stockholders | |||||
| Diluted loss per share attributable to common stockholders |
Loading...